Details of the Drug Combination

General Information of Drug Combination (ID: DC6TTUR)

Drug Combination Name

Topetecan Topetecan

Indication

Disease Entry	Status	REF
Diffuse large B cell lymphoma	Investigative	[1]

Component Drugs

Topetecan DMAE6LK

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: TMD8

Zero Interaction Potency (ZIP) Score: 9.026

Bliss Independence Score: 7.406

Loewe Additivity Score: 5.051

LHighest Single Agent (HSA) Score: 8.857

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Topetecan

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Approved	[2]

Topetecan Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

Indication(s) of Topetecan

Disease Entry	ICD 11	Status	REF
Small-cell lung cancer	2C25.Y	Approved	[2]

Topetecan Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020671.
3	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).